Edward Md Kaye Sells 25,000 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward Md Kaye sold 25,000 shares of Stoke Therapeutics stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $30.00, for a total transaction of $750,000.00. Following the completion of the sale, the director owned 49,124 shares in the company, valued at approximately $1,473,720. This represents a 33.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $30.19 on Friday. The company has a market cap of $1.65 billion, a P/E ratio of 35.52 and a beta of 1.24. The firm’s 50 day simple moving average is $20.97 and its 200-day simple moving average is $13.87. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $32.40.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. The business had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. On average, analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its position in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares during the last quarter. GAMMA Investing LLC lifted its stake in Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after acquiring an additional 5,084 shares during the period. Osaic Holdings Inc. increased its holdings in shares of Stoke Therapeutics by 263.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock valued at $85,000 after acquiring an additional 5,427 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in Stoke Therapeutics by 33.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock worth $108,000 after buying an additional 2,384 shares during the last quarter.

Analyst Ratings Changes

STOK has been the subject of a number of recent research reports. Jefferies Financial Group began coverage on shares of Stoke Therapeutics in a research note on Friday, July 18th. They set a “buy” rating and a $30.00 price target for the company. Needham & Company LLC raised their target price on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. Weiss Ratings reissued a “sell (d+)” rating on shares of Stoke Therapeutics in a research report on Wednesday. BTIG Research set a $28.00 target price on Stoke Therapeutics and gave the company a “buy” rating in a report on Monday, August 18th. Finally, Wedbush increased their price target on Stoke Therapeutics from $16.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $27.43.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.